Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 7/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 6/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3683970 | 0.92 | ROCK2 (0.51) | ROCK2SCD5PROKR1RBP4KDM5A | |
| SCHEMBL3683430 | 0.92 | SCD5 (0.42) | ROCK2SCD5PROKR1RBP4CNR1 | |
| SCHEMBL3696196 | 0.92 | ROCK2 (0.43) | ROCK2SCD5PROKR1RBP4CNR1 | |
| SCHEMBL4453264 | 0.91 | SCD5 (0.42) | ROCK2SCD5PROKR1RBP4CNR1 | |
| SCHEMBL3685882 | 0.91 | SCD5 (0.44) | ROCK2SCD5PROKR1RBP4CNR1 | |
| SCHEMBL3688270 | 0.89 | SCD5 (0.51) | SCD5RBP4CNR1 | |
| SCHEMBL3697888 | 0.87 | PROKR1 (0.41) | ROCK2PROKR1RBP4 | |
| SCHEMBL3704741 | 0.87 | ROCK2 (0.40) | ROCK2SCD5PROKR1RBP4KDM5A | |
| SCHEMBL3687818 | 0.86 | SCD5 (0.47) | SCD5RBP4CNR1NAMPT | |
| SCHEMBL3691914 | 0.86 | SCD5 (0.44) | SCD5RBP4CNR1KDM5APARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| CN-101842098-A | Nitrogen-containing bicyclic chemical entities for the treatment of viral infections | GENELABS TECH INC | 2010-09-22 | — | — | CN | disclosed |
| EP-2187883-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2009023179-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | OAT, HAVCR2, CPS1 | ROCK2 4811/4885SCD5 2314/4885PROKR1 4829/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | ROCK2 4811/4885SCD5 2314/4885PROKR1 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.